Management of immune related adverse events induced by immune checkpoint inhibition
In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy and these drugs have already become essential for the treatment of various non-curable tumors. Compared to conventional chemotherapy or tyrosine kinase inhibitors, ICIs generally exhibit a favorable s...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
9 April 2019
|
| In: |
Cancer letters
Year: 2019, Jahrgang: 456, Pages: 80-87 |
| ISSN: | 1872-7980 |
| DOI: | 10.1016/j.canlet.2019.04.018 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.canlet.2019.04.018 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0304383519302435 
|
| Verfasserangaben: | Andreas Teufel, Tianzuo Zhan, Nicolai Härtel, Jan Bornschein, Matthias P. Ebert, Nadine Schulte |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1681974991 | ||
| 003 | DE-627 | ||
| 005 | 20230428191324.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191115s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2019.04.018 |2 doi | |
| 035 | |a (DE-627)1681974991 | ||
| 035 | |a (DE-599)KXP1681974991 | ||
| 035 | |a (OCoLC)1341250485 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Teufel, Andreas |d 1971- |e VerfasserIn |0 (DE-588)121120031 |0 (DE-627)081100035 |0 (DE-576)292546750 |4 aut | |
| 245 | 1 | 0 | |a Management of immune related adverse events induced by immune checkpoint inhibition |c Andreas Teufel, Tianzuo Zhan, Nicolai Härtel, Jan Bornschein, Matthias P. Ebert, Nadine Schulte |
| 264 | 1 | |c 9 April 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 15.11.2019 | ||
| 520 | |a In recent years, immune checkpoint inhibitors (ICIs) were successfully introduced to cancer therapy and these drugs have already become essential for the treatment of various non-curable tumors. Compared to conventional chemotherapy or tyrosine kinase inhibitors, ICIs generally exhibit a favorable side effect profile further promoting their increasing prescription rate. However, increasing use of these substance made clear that ICI induced activation of the immune system may also lead to immune-related adverse events (irAEs). Common irAEs are dermatological, gastrointestinal, or endocrine side effects but further tissue types and organ systems may also be affected. A detailed knowledge of these potential side effects is important as early recognition is the key to successful treatment, reversibility of organ dysfunction and in some cases even prevention of fatal outcome. In more severe irAEs, immunosuppression may be necessary to cope with these side effects. To increase awareness of irAEs and support immediate and successful management, we provide a comprehensive review on most common irAEs of ICIs, their diagnosis, and treatment. | ||
| 650 | 4 | |a Checkpoint blockade | |
| 650 | 4 | |a CTLA-4 | |
| 650 | 4 | |a Immune related adverse events | |
| 650 | 4 | |a Ipilimumab | |
| 650 | 4 | |a irAE | |
| 650 | 4 | |a Nivolumab | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a PD-L1 | |
| 650 | 4 | |a Pembrolizumab | |
| 700 | 1 | |a Zhan, Tianzuo |d 1985- |e VerfasserIn |0 (DE-588)1019998911 |0 (DE-627)691070105 |0 (DE-576)359019544 |4 aut | |
| 700 | 1 | |a Härtel, Nicolai |d 1977- |e VerfasserIn |0 (DE-588)129912913 |0 (DE-627)483650609 |0 (DE-576)297899821 |4 aut | |
| 700 | 1 | |a Bornschein, Jan Alexander |d 1980- |e VerfasserIn |0 (DE-588)133951022 |0 (DE-627)558830099 |0 (DE-576)300212585 |4 aut | |
| 700 | 1 | |a Ebert, Matthias |d 1968- |e VerfasserIn |0 (DE-588)1030133522 |0 (DE-627)734827083 |0 (DE-576)377938432 |4 aut | |
| 700 | 1 | |a Schulte, Nadine |d 1981- |e VerfasserIn |0 (DE-588)138942404 |0 (DE-627)703158511 |0 (DE-576)308939069 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d Amsterdam [u.a.] : Elsevier Science, 1975 |g 456(2019), Seite 80-87 |h Online-Ressource |w (DE-627)320434796 |w (DE-600)2004212-7 |w (DE-576)261677926 |x 1872-7980 |7 nnas |a Management of immune related adverse events induced by immune checkpoint inhibition |
| 773 | 1 | 8 | |g volume:456 |g year:2019 |g pages:80-87 |g extent:8 |a Management of immune related adverse events induced by immune checkpoint inhibition |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.canlet.2019.04.018 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0304383519302435 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20191115 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 138942404 |a Schulte, Nadine |m 138942404:Schulte, Nadine |d 60000 |d 61100 |e 60000PS138942404 |e 61100PS138942404 |k 0/60000/ |k 1/60000/61100/ |p 6 |y j | ||
| 998 | |g 1030133522 |a Ebert, Matthias |m 1030133522:Ebert, Matthias |d 60000 |d 61100 |e 60000PE1030133522 |e 61100PE1030133522 |k 0/60000/ |k 1/60000/61100/ |p 5 | ||
| 998 | |g 129912913 |a Härtel, Nicolai |m 129912913:Härtel, Nicolai |d 60000 |d 61100 |e 60000PH129912913 |e 61100PH129912913 |k 0/60000/ |k 1/60000/61100/ |p 3 | ||
| 998 | |g 1019998911 |a Zhan, Tianzuo |m 1019998911:Zhan, Tianzuo |d 60000 |d 61100 |e 60000PZ1019998911 |e 61100PZ1019998911 |k 0/60000/ |k 1/60000/61100/ |p 2 | ||
| 998 | |g 121120031 |a Teufel, Andreas |m 121120031:Teufel, Andreas |d 60000 |d 61100 |e 60000PT121120031 |e 61100PT121120031 |k 0/60000/ |k 1/60000/61100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1681974991 |e 3540674624 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Andreas Teufel, Tianzuo Zhan, Nicolai Härtel, Jan Bornschein, Matthias P. Ebert, Nadine Schulte"]},"recId":"1681974991","id":{"doi":["10.1016/j.canlet.2019.04.018"],"eki":["1681974991"]},"origin":[{"dateIssuedDisp":"9 April 2019","dateIssuedKey":"2019"}],"physDesc":[{"extent":"8 S."}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"family":"Teufel","role":"aut","given":"Andreas","display":"Teufel, Andreas"},{"family":"Zhan","role":"aut","given":"Tianzuo","display":"Zhan, Tianzuo"},{"given":"Nicolai","role":"aut","family":"Härtel","display":"Härtel, Nicolai"},{"given":"Jan Alexander","role":"aut","family":"Bornschein","display":"Bornschein, Jan Alexander"},{"display":"Ebert, Matthias","family":"Ebert","role":"aut","given":"Matthias"},{"display":"Schulte, Nadine","role":"aut","given":"Nadine","family":"Schulte"}],"title":[{"title_sort":"Management of immune related adverse events induced by immune checkpoint inhibition","title":"Management of immune related adverse events induced by immune checkpoint inhibition"}],"relHost":[{"part":{"year":"2019","extent":"8","text":"456(2019), Seite 80-87","pages":"80-87","volume":"456"},"origin":[{"publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier Science","dateIssuedKey":"1975","dateIssuedDisp":"1975-"}],"id":{"eki":["320434796"],"issn":["1872-7980"],"zdb":["2004212-7"]},"disp":"Management of immune related adverse events induced by immune checkpoint inhibitionCancer letters","recId":"320434796","title":[{"subtitle":"an international journal providing a forum for original and pertinent contributions in cancer research","title":"Cancer letters","title_sort":"Cancer letters"}],"language":["eng"],"pubHistory":["1.1975 -"],"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 22.01.2020"],"type":{"media":"Online-Ressource","bibl":"periodical"}}],"note":["Gesehen am 15.11.2019"]} | ||
| SRT | |a TEUFELANDRMANAGEMENT9201 | ||